September 18, 2009 โ The FDA has approved Valturna (aliskiren and valsartan) tablets, the first and only medicine ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
September 17, 2009 โ The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) on ...
In August Daiichi Sankyo and Eli Lilly and Company launched U.S. sales of Effient (prasugrel), a new antiplatelet ...
September 14, 2009 โ The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today ...
Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in ...
September 10, 2009 โ Regado Biosciences said this week it enrolled the first patient in a phase 2b, randomized ...
September 8, 2009 โ Actelion Pharmaceuticals U.S. Inc. recently announced the first commercial sales of a new 20 ...
September 3, 2009 โ Important new findings in patients with angina participating in the BEAUTIFUL study show that ...
September 3, 2009 โ The OASIS study group presented initial results of the CURRENT-OASIS 7 clinical trial Sunday ...
September 2, 2009 โ A new analysis from the JUPITER study showed CRESTOR (rosuvastatin calcium) 20 mg reduced the ...
September 1, 2009 โ Cordis Corp. said first patient has been enrolled in the CYPRESS study, which will assess ...
September 1, 2009 โ Sanofi-aventis said Sunday the investigational anti-Xa intravenous anti-coagulant otamixaban ...
September 1, 2009 โ AstraZeneca last week announced results from the phase III head to head trial, PLATO (A Study ...
August 13, 2009 โ Abbott today announced the expansion of the company's XIENCE V USA post-approval study designed ...
August 13, 2009 โ The pharmaceutical and healthcare research firm Decision Resources found Merck/Schering-Plough ...